ES2168294T3 - Derivados de tiazol o imidazol inhibidores de la reaccion de maillard. - Google Patents

Derivados de tiazol o imidazol inhibidores de la reaccion de maillard.

Info

Publication number
ES2168294T3
ES2168294T3 ES94907081T ES94907081T ES2168294T3 ES 2168294 T3 ES2168294 T3 ES 2168294T3 ES 94907081 T ES94907081 T ES 94907081T ES 94907081 T ES94907081 T ES 94907081T ES 2168294 T3 ES2168294 T3 ES 2168294T3
Authority
ES
Spain
Prior art keywords
pct
maillard
reaction
tiazol
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907081T
Other languages
English (en)
Inventor
Koichi Yasumura
Keisuke Miyajima
Takao Nagahama
Shintaro Ishikawa
Yuko Nakagawa
Kazuhisa Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2168294T3 publication Critical patent/ES2168294T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN COMPUESTO REPRESENTADO POR FORMULA (I), EN DONDE TODOS LOS SIMBOLOS SON DEFINIDOS EN LA MEMORIA. UN PROCESO PARA PRODUCIR EL COMPUESTO, Y TAMBIEN SE DESCRIBE UN METODO PARA TRATAR ENFERMEDADES CAUSADAS POR UNA REACCION DE MAILLARD EN CUERPO VIVO USANDO EL COMPUESTO.
ES94907081T 1993-02-26 1994-02-21 Derivados de tiazol o imidazol inhibidores de la reaccion de maillard. Expired - Lifetime ES2168294T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3772093 1993-02-26
JP23024393 1993-09-16

Publications (1)

Publication Number Publication Date
ES2168294T3 true ES2168294T3 (es) 2002-06-16

Family

ID=26376862

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907081T Expired - Lifetime ES2168294T3 (es) 1993-02-26 1994-02-21 Derivados de tiazol o imidazol inhibidores de la reaccion de maillard.

Country Status (14)

Country Link
US (1) US5677322A (es)
EP (1) EP0638075B1 (es)
JP (2) JP2821661B2 (es)
KR (2) KR100250701B1 (es)
CN (2) CN1037842C (es)
AT (1) ATE212018T1 (es)
AU (1) AU669427B2 (es)
CA (1) CA2134347C (es)
DE (1) DE69429641T2 (es)
DK (1) DK0638075T3 (es)
ES (1) ES2168294T3 (es)
PT (1) PT638075E (es)
TW (1) TW338041B (es)
WO (1) WO1994019335A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
US5955617A (en) 1996-05-21 1999-09-21 Pharmacia & Upjohn Company Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
AU6518598A (en) * 1997-03-28 1998-10-22 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6
EP2070535B1 (en) 1998-08-24 2015-07-08 Kurokawa, Kiyoshi Drugs for relieving carbonyl stress and peritoneal dialysates
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
US6265571B1 (en) 1999-07-12 2001-07-24 Magellan Laboratories, Inc. Purification process for anti-parasitic fermentation product
DE10052590A1 (de) * 2000-10-24 2002-05-02 Haarmann & Reimer Gmbh Verwendung von 2-Hydrazino-1,3-thiazolen als Antioxidantien
JP4711523B2 (ja) 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
WO2002085855A1 (fr) * 2001-04-19 2002-10-31 Eisai Co., Ltd. Derives de 2-iminopyrrolidine
US7705120B2 (en) 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
EP2444393A1 (en) * 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
US20050059790A1 (en) * 2003-09-16 2005-03-17 Roesler Richard R. Process for preparing aspartates
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
HRP20100714T1 (hr) 2003-11-21 2011-01-31 Actelion Pharmaceuticals Ltd. Derivati 5-(benz-(z)-iliden)-tiazolidin-4-ona kao imunosupresivna sredstva
EP1707560A4 (en) * 2003-12-25 2007-10-17 Kureha Corp HYDROXAMIC ACID DERIVATIVE AND THE DERIVATIVE INHIBITOR OF THE GENERATION OF AGE
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
AU2007323042B2 (en) * 2006-11-23 2012-12-20 Laboratoires Juvise Pharmaceuticals New process for the preparation of 2-imino-thiazolidin-4-one derivatives
LT2885266T (lt) 2012-08-17 2020-07-10 Actelion Pharmaceuticals Ltd (2z,5z)-5-(3-chlor-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ono gamybos būdas ir šiame procese naudojamas tarpinis junginys
GB201405991D0 (en) * 2014-04-03 2014-05-21 Cambridge Entpr Ltd Novel compounds
CN107459496B (zh) * 2016-06-03 2022-07-19 华东理工大学 噻唑类衍生物在治疗病毒感染中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528844A1 (fr) * 1982-06-18 1983-12-23 Chauvin Blache Lab Nouvelles thiazolyl-2 hydrazones, leur procede de preparation et leur application en therapeutique
US5258381A (en) * 1984-03-19 1993-11-02 The Rockefeller University 2-substituted-2-imidazolines
EP0325936A3 (en) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidine derivatives and inhibitory agents on maillard reaction containing them as active ingredients
TW221689B (es) * 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd

Also Published As

Publication number Publication date
CN1067992C (zh) 2001-07-04
KR100250701B1 (ko) 2000-07-01
DE69429641D1 (en) 2002-02-21
KR100257180B1 (ko) 2000-05-15
AU669427B2 (en) 1996-06-06
CA2134347A1 (en) 1994-08-27
DE69429641T2 (de) 2002-08-29
PT638075E (pt) 2002-06-28
KR950701328A (ko) 1995-03-23
AU6045894A (en) 1994-09-14
WO1994019335A1 (en) 1994-09-01
US5677322A (en) 1997-10-14
DK0638075T3 (da) 2002-02-18
EP0638075B1 (en) 2002-01-16
JPH10167965A (ja) 1998-06-23
EP0638075A1 (en) 1995-02-15
TW338041B (en) 1998-08-11
JPH07133264A (ja) 1995-05-23
CN1184105A (zh) 1998-06-10
CA2134347C (en) 2003-04-29
ATE212018T1 (de) 2002-02-15
JP2821661B2 (ja) 1998-11-05
CN1106982A (zh) 1995-08-16
CN1037842C (zh) 1998-03-25

Similar Documents

Publication Publication Date Title
ES2168294T3 (es) Derivados de tiazol o imidazol inhibidores de la reaccion de maillard.
DK0828741T3 (da) Spirocykliske og bicykliske diazinyl- og carbazinyloxazolidinoner
ZA953469B (en) New compound
EP0641204A4 (en) 17-ETHER AND THIOETHER OF 4-AZA STEROIDS.
EP0649306A4 (en) ESTER DERIVATIVES OF 4-AZA STEROIDS.
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
NO943475D0 (no) Forbindelse for å regulere fethet i hud
FI943948A0 (fi) Heterosykliset hiilihappojohdannaiset
DK0696281T3 (da) Hidtil ukendte 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazolderivater
AU2002356991A1 (en) Amino acid derivatives useful for the treatment of alzheimer's disease
EP0774462A4 (en) HETEROCYCLIC COMPOUND
PL317349A1 (en) Organic compounds
HUT71512A (en) N-(3-chlorophenyl)-piperazine derivatives for producing alkyl-trazodon derivatives and process for producing them
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
NO20003481L (no) FremgangsmÕte for behandling av COPD
IL117083A0 (en) Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical agents containing these compounds
PT99280A (pt) Processo de preparacao de derivados do indolo e de composicoes farmaceuticas
ATE173259T1 (de) Verfahren zur herstellung von indolizinderivaten
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 638075

Country of ref document: ES